1. CCAT1: an oncogenic long noncoding RNA in human cancers

   • Xiaoqiang Guo
   • Yuming Hua

   Review – Cancer Research 16 September 2016 Pages: 555 - 562

   

2. Men and women show similar survival rates after breast cancer

   • Paulo Franscisco Mascarenhas Bender
   • Letícia Lima de Oliveira
   • Luiz Claudio Santos Thuler

   Original Article – Cancer Research 08 December 2016 Pages: 563 - 571

   

3. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines

   • Julia Kneissl
   • Anja Hartmann
   • Birgit Luber

   Original Article – Cancer Research Open access 08 December 2016 Pages: 573 - 600

   

4. Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer

   • Weiwei Liang
   • Zhiwei Xie
   • Hongyu Guan

   Original Article – Cancer Research 10 December 2016 Pages: 601 - 611

   

5. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients

   • Richard Ofner
   • Cathrin Ritter
   • Jürgen C. Becker

   Original Article – Cancer Research 18 December 2016 Pages: 613 - 617

6. Identification of a prognostic 5-Gene expression signature for gastric cancer

   • Jun-Yi Hou
   • Yu-Gang Wang
   • Qian-Ping Li

   Original Article – Cancer Research 29 December 2016 Pages: 619 - 629

   

7. A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer

   • Jing Ma
   • Jichun Yang
   • Duan Ma

   Original Article – Cancer Research 05 January 2017 Pages: 631 - 637

   

8. Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells

   • Hui Liu
   • Min Zhu
   • Weicheng Xue

   Original Article – Cancer Research 16 January 2017 Pages: 639 - 648

   

9. Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics

   • Agnieszka Klupczynska
   • Paweł Dereziński
   • Zenon J. Kokot

   Original Article – Cancer Research Open access 06 February 2017 Pages: 649 - 659

   

10. Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme

    • Jia-Bin Wang
    • Feng-Hua Liu
    • Zhi-Guo Lin

    Original Article – Cancer Research 06 February 2017 Pages: 661 - 671

    

11. Current developments in cancer care: including the patients’ perspective—3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany

    • O. Ortmann
    • W. Rösler
    • for the participants of the ERTM

    Review – Clinical Oncology 17 December 2016 Pages: 673 - 676

12. Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization

    • Johannes Mischinger
    • Lutz Philipp Guttenberg
    • Tilman Todenhöfer

    Original Article – Clinical Oncology 02 December 2016 Pages: 677 - 685

    

13. Preoperative characteristics of the P.R.O.S.T.A.T.E. scores: a novel predictive tool for the risk of positive surgical margin after radical prostatectomy

    • Ben Xu
    • Cheng Luo
    • Jie Jin

    Original Article – Clinical Oncology 05 December 2016 Pages: 687 - 692

    

14. Fingerprint changes among cancer patients treated with paclitaxel

    • Payam Azadeh
    • Simin Dashti-Khavidaki
    • Maryam Farasatinasab

    Original Article – Clinical Oncology 17 December 2016 Pages: 693 - 701

    

15. Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up

    • Thomas Kurt Eigentler
    • Joachim Hinderer
    • Ulrike Leiter

    Original Article – Clinical Oncology 19 December 2016 Pages: 703 - 708

    

16. Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation

    • Osamu Imataki
    • Kensuke Matsumoto
    • Makiko Uemura

    Original Article – Clinical Oncology 06 January 2017 Pages: 709 - 715

    

17. A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors

    • Constantinos E. Alifieris
    • Kyriakos Orfanakos
    • Dimitrios T. Trafalis

    Original Article – Clinical Oncology 11 January 2017 Pages: 717 - 725

    

18. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

    • Jian-Xian Lin
    • Qing-Feng Chen
    • Chang-Ming Huang

    Original Article – Clinical Oncology 12 January 2017 Pages: 727 - 734

    

19. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting

    • Thomas M. Atkinson
    • Lauren J. Rogak
    • Yuelin Li

    Original Article – Clinical Oncology 16 January 2017 Pages: 735 - 743